Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov .
Updates regarding government operating status and resumption of normal operations can be found at OPM.gov .

Dr. Richard Schneiderman

Dr. Richard Schneiderman

Scientific Review Officer



Biography

Division:
Division of Translational and Clinical Sciences DTCS
Review Branch:
Respiratory, Cardiac, and Circulatory Sciences RCCS
Study Section:
Therapeutic Development and Preclinical Studies TDPS

Dr. Richard Schneiderman received his Ph.D. in immunology from The University of Illinois, Chicago, where he studied cellular and molecular mechanisms regulating immunoglobulin A expression and function. He completed postdoctoral training in retroviral biology and gene therapy initially at Genetic Therapy Inc. in Gaithersburg, MD. Dr. Schneiderman then served in the Laboratory of Cell Biology at the NIH National Institute of Mental Health, investigating vector biology, receptor interaction and host restriction. He then moved to Baxter Healthcare Corporation, where he was a Principal Scientist investigating a number of gene and cell therapy approaches for hemophilia and diabetes. Before coming to CSR, Dr. Schneiderman was a Principal Scientist at Boehringer Ingelheim Pharmaceuticals and Acorda Therapeutics investigating therapeutic treatments for cardiovascular diseases including atherosclerosis, heart failure, and hypertension.

 

Last updated: 08/27/2025 05:03